Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Campbell

Advanced Heart Failure and Transplant Cardiology Little Rock, AR Medical Doctor

NPI 1215113154 CMS profile 54496

9500 Kanis Rd Ste 410, Little Rock, AR 72205

Open in the dashboard

General payments

$102,262

997 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$83,729 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Patrick Campbell of Little Rock, AR is reported in the CMS Open Payments database as having received $102,262 across 997 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $83,729 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,669 179
2024 General $32,319 179
2023 General $31,596 169
2022 General $4,863 133
2021 General $3,936 118
2020 General $2,047 75
2019 General $20,833 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Campbell
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Patrick Campbell were reported at $6,669. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Patrick Campbell Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $20,833 $863 $224–$4,562 $163
2020 $2,047 $452 $122–$3,992 $114
2021 $3,936 $550 $159–$3,571 $132
2022 $4,863 $729 $221–$4,357 $149
2023 $31,596 $1,002 $309–$5,827 $160
2024 $32,319 $931 $273–$5,204 $164
2025 $6,669 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $25,979 73 payments
  2. Pfizer Inc. $14,902 82 payments
  3. Novartis Pharmaceuticals Corporation $13,977 85 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $10,649 98 payments
  5. Abbott Laboratories $9,816 121 payments
  6. Actelion Pharmaceuticals US, Inc. $9,302 134 payments
  7. Lilly USA, LLC $5,227 4 payments
  8. Abiomed $2,294 46 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $1,934 22 payments
  10. United Therapeutics Corporation $1,809 52 payments
  11. Other $6,372 280 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,980 23 payments
  2. Food and Beverage $22,928 923 payments
  3. Consulting Fee $12,580 9 payments
  4. Travel and Lodging $9,108 27 payments
  5. Education $666 15 payments
Products named General payments · program years 2019–2025
  1. AMVUTTRA $18,844 32 payments
  2. VYNDAQEL $14,656 62 payments
  3. ENTRESTO $13,587 62 payments
  4. JARDIANCE Diabetes $9,593 29 payments
  5. OPSUMIT $8,865 118 payments
  6. UPTRAVI $8,859 112 payments
  7. ONPATTRO $7,135 41 payments
  8. JARDIANCE Diabetes $5,200 2 payments
  9. HeartMate 3 Left Ventricular Dev $3,909 16 payments
  10. Adempas $1,635 13 payments
  11. Other $18,699 661 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,545

Median for Internal Medicine: 777

Drug cost

$6,963,108

Median for Internal Medicine: $73,373

Branded share of claims

28%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opsumit Macitentan Brand 156 $1,957,109
Uptravi Selexipag Brand 51 $1,117,393
Vyndamax Tafamidis Brand 32 $935,982
Adempas Riociguat Brand 50 $702,286
Tyvaso Dpi Treprostinil Brand 28 $654,707
Orenitram Er Treprostinil Diolamine Brand 27 $417,056
Camzyos Mavacamten Brand 28 $234,621
Entresto Sacubitril/Valsartan Brand 262 $219,763
Winrevair Sotatercept-Csrk Brand 11 $163,722
Jardiance Empagliflozin Brand 144 $115,830

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$97,428

Medicare's payments for the services billed

Medicare patients

243

Average age 65

Services billed

1,841

92 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 69%
Chronic kidney disease 60%
Atrial fibrillation 59%
Diabetes 49%
Arthritis 36%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$12,864 144 —
VYNDAQEL
$6,769 — —
OPSUMIT
$3,298 156 —
UPTRAVI
$3,235 51 —
AMVUTTRA
$2,472 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

997 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record